The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019

Amendment of Schedule 5 (review upon oral representations)U.K.

This section has no associated Explanatory Memorandum

22.—(1) Schedule 5 M1 is amended as follows.

(2) In paragraph 1(2)(e), 3(11)(b) and 5(2)(d) after—

(a)“UK marketing authorisation,” in each place it appears, insert “ parallel import licence, ”; and

(b)“an authorisation,” or “the authorisation,” in each place it appears, insert “ licence, ”.

(3) In paragraph 3 omit sub-paragraph (11)(b)(iii).

(4) In paragraph 5 omit sub-paragraph (2)(c).

Commencement Information

I1Reg. 22 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1

Marginal Citations

M1Schedule 5 was amended by S.I. 2013/1855.